Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
about
Understanding and treating triple-negative breast cancerUptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancerBrain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatmentBreast cancer brain metastases: the last frontierEmerging treatment options for the management of brain metastases in patients with HER2-positive metastatic breast cancerBreast cancer chemoprevention: old and new approachesTargeted Therapies for Brain Metastases from Breast CancerMolecular Mechanisms and Metabolomics of Natural Polyphenols Interfering with Breast Cancer MetastasisDexamethasone-(C21-phosphoramide)-[anti-EGFR]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency against pulmonary adenocarcinoma (A549)Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma.Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.Treatment of vestibular schwannoma cells with ErbB inhibitorsErbB/HER receptor activation and preclinical efficacy of lapatinib in vestibular schwannoma.Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial.Blood vessel morphologic changes depicted with MR angiography during treatment of brain metastases: a feasibility study.Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer modelGemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549)Carmustine and methotrexate in combination after whole brain radiation therapy in breast cancer patients presenting with brain metastases: a retrospective study.Current approaches to the treatment of metastatic brain tumours.Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.Progress in the biological understanding and management of breast cancer-associated central nervous system metastases.Voxelwise single-subject analysis of imaging metabolic response to therapy in neuro-oncologyProfound prevention of experimental brain metastases of breast cancer by temozolomide in an MGMT-dependent manner.TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2014.Brain Metastases of Her2-Positive Breast Cancer: A Case of 34 Months' Remission with Lapatinib plus Capecitabine.Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study.Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors.Targeting HER2 in breast cancer: overview of long-term experienceTargeted treatment of advanced and metastaticbreast cancer with lapatinib.Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.The molecular genomics of metastatic brain tumours.Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome.Lapatinib-induced hepatitis: a case report.Human epidermal growth factor receptor-2-positive breast cancer: Current management of early, advanced, and recurrent disease.A novel preclinical method to quantitatively evaluate early-stage metastatic events at the murine blood-brain barrierEmerging strategies for treating brain metastases from breast cancer.Triple-negative breast cancers: an updated review on treatment options
P2860
Q24620957-66FAAC91-9CDD-4A73-B0A5-121636393568Q24621947-AA55F28F-2593-4714-9113-D10880B85EA4Q26751008-DE8E76B2-528D-4720-B4E9-A2686E5A27C0Q26775663-9E7193FB-F4FD-4B14-868C-B200F0DF5B91Q26824799-73D87B49-7155-4BE3-9C4D-D266866566F9Q27693259-A4A85EDA-C480-42D5-A2D0-279E967F1E1CQ28068154-A75D7DCD-4023-412D-8798-95694406FE9DQ28076953-141F6238-AEED-43E1-BC4F-DA2D44A12194Q28829762-0E1DDC09-1784-463B-B218-AB09C0BDD1AAQ30239901-1B518533-E775-4EFA-A88C-957907956FA3Q30450038-C5E82078-4941-4F5A-B6D4-D4CA9DE26AB2Q30458767-BB5ED423-3E47-4996-B053-6BC354E0F9DFQ30474678-E8211F6E-D1F7-4D94-92DA-1249B27680F0Q30758991-B13637AC-E65A-4100-986F-37C85236EAB2Q31133970-7D6CB1E3-8A09-458D-8DC2-5D6CF3D10D7BQ33575434-6BA7A732-F712-4284-A03F-01744B9DFC2FQ33578254-A38F2564-38A0-4E38-B43F-828F900884C3Q33595274-E95AC2F9-9FB7-4823-A91A-E3F778984686Q33696559-BDB7DACA-8723-493F-9A4B-10508DB3D061Q33747400-EA8367DF-ECB9-4E96-B2E2-4EB99234A26EQ33777436-23148CE4-3AFF-4ECD-A298-5548E7D34CE6Q33835371-71598881-54D1-46D9-AE75-3830D706E261Q33909294-D65B76DA-F9D3-44D6-9042-2D17954E8377Q33954557-27F2D740-A64C-4BFD-94F2-A6889330B66AQ34042768-BF557510-2AB3-4762-92D5-1C62036D5E86Q34181224-080AE76A-4310-4987-85BE-F521F7E68676Q34193975-BD2F2722-05AF-42F3-9080-EFBFCFEE5FD2Q34241118-7CD3331D-EED5-40DD-9B62-ACFEA05BADE2Q34253243-195192D3-CB2A-43CE-8E25-E4C4F250C904Q34272044-FFEF90A4-82BF-4E7B-ACF4-39FA66AB3688Q34363419-AD3729C9-D13A-4A79-9975-1881BDC92A0AQ34417920-B9841FDC-5B16-4DC8-983F-D096D89BA902Q34499855-FEA8F4E3-03D9-45B2-94EA-48AD593E1790Q34886764-29FB9346-783E-49BA-8188-7D55547A935DQ34990356-78C29ACC-7E23-4C9D-9A2E-83DA33CAB279Q34993721-6855DFAF-1D09-4D72-9F0D-E8D3A703E543Q35018233-3E947FC4-17F6-4376-BA6D-C3B5937C9FEAQ35030625-F7CBA4D2-07F1-4AE1-829F-C00E3193D8C6Q35075446-9CDCD94D-4AF7-4E15-ABED-9EC2F997DB1CQ35145678-9F6E5D8D-454E-4B26-B599-BE096F437B65
P2860
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Phase II trial of lapatinib fo ...... ptor 2-positive breast cancer.
@ast
Phase II trial of lapatinib fo ...... ptor 2-positive breast cancer.
@en
type
label
Phase II trial of lapatinib fo ...... ptor 2-positive breast cancer.
@ast
Phase II trial of lapatinib fo ...... ptor 2-positive breast cancer.
@en
prefLabel
Phase II trial of lapatinib fo ...... ptor 2-positive breast cancer.
@ast
Phase II trial of lapatinib fo ...... ptor 2-positive breast cancer.
@en
P2093
P2860
P356
P1476
Phase II trial of lapatinib fo ...... ptor 2-positive breast cancer.
@en
P2093
Ann Crawford
Annick D Van den Abbeele
David G Kirsch
Elizabeth Bullitt
Elizabeth Kasparian
Eric P Winer
Fred Hochberg
Gordon J Harris
Harold J Burstein
Jerry Younger
P2860
P304
P356
10.1200/JCO.2007.12.3588
P407
P577
2008-04-01T00:00:00Z